Keystone Capital Partners
Keystone Capital Partners is a private equity investment firm based in New York, founded in 2019. The firm focuses on providing capital solutions to overlooked and underfunded companies, enabling them to achieve their objectives through stable and equitable financing. Keystone aims to identify attractively valued micro-cap, small-cap, and mid-cap public and private equity investments by employing a bottom-up, fundamental analysis approach. Its investment strategy encompasses sectors such as biotechnology, real estate, and consumer products, reflecting a commitment to supporting a diverse range of industries.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company based in Charlottesville, Virginia, focused on developing treatments for addiction and related disorders. Founded in 2010, the company’s primary product is AD04, a selective serotonin-3 antagonist that has completed a Phase IIb study aimed at treating alcohol use disorder. Additionally, Adial is advancing AD01, which has completed Phase I clinical trials and targets various addictive behaviors. The company is dedicated to addressing the growing issue of addiction through innovative pharmaceutical solutions.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company based in Charlottesville, Virginia, focused on developing treatments for addiction and related disorders. Founded in 2010, the company’s primary product is AD04, a selective serotonin-3 antagonist that has completed a Phase IIb study aimed at treating alcohol use disorder. Additionally, Adial is advancing AD01, which has completed Phase I clinical trials and targets various addictive behaviors. The company is dedicated to addressing the growing issue of addiction through innovative pharmaceutical solutions.
AnPac Bio-Medical Science Co., Ltd. is a development-stage biotechnology company based in Lishui, China, founded in 2010. The company specializes in the research, development, marketing, and sale of multi-cancer screening and detection tests targeted at corporations and life insurance companies in China and the United States. AnPac is recognized for its innovative Cancer Differentiation Analysis (CDA) program, which utilizes proprietary medical devices to perform blood biopsies. This technology significantly enhances the sensitivity and specificity of cancer detection without causing side effects for patients. AnPac's CDA diagnostics have been validated through over 22,000 cases, demonstrating the capability to detect early signals of cancer and identify the type and location of the disease, often before tumors develop. In addition to its diagnostic services, AnPac also manufactures cancer differentiation analysis devices and offers physical checkup package services.
Stella Diagnostics, LLC, a molecular diagnostics-based organization, focuses on improving patient management strategies for the people living with severe esophageal disease. Its mass spec proteomic assays offer physicians insight into the molecular properties of their patients’ tissue to determine if the disease is stable, progressing, or turning cancerous. The company is based in New York, New York. As of September 2, 2020, Stella Diagnostics, LLC operates as a subsidiary of JMD Properties Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.